Anavex Life Sciences Corp. announced on September 2, 2026, that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following a delinquency notification received in May 2026 due to the late filing of its Form 10-Q for the period ended March 31, 2026. The company submitted a compliance plan on July 20, 2026, and filed the outstanding quarterly reports for the periods ended March 31 and June 30, 2026, on August 28, 2026. Nasdaq confirmed the restoration of compliance, allowing Anavex's common stock to continue trading on the Nasdaq Global Select Market under the ticker AVXL without further delisting risk related to this specific filing requirement. This resolution mitigates near-term operational uncertainty regarding exchange listing status for the clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.

Anavex Life Sciences Corp. reported financial results for the third fiscal quarter ended June 30, 2026, posting a net income of $7.8 million, or $0.08 per share, compared to a net loss of $13.2 million in the prior year period. The turnaround was driven by reversals of stock-based compensation expense totaling $17.4 million associated with employee terminations, primarily the former CEO. Cash and cash equivalents rose to $118.3 million from $102.6 million at fiscal year-end September 30, 2025, providing a runway into mid-to-late fiscal 2028. Clinically, the company submitted all Alzheimer’s disease trial data to its new IND and plans to discuss Phase 3 protocol design with the FDA. It also submitted an FDA meeting request for Rett syndrome pediatric inclusion and expects to file an IND for Fragile X syndrome in September. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing treatments for central nervous system diseases.

Anavex Life Sciences Corp. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders scheduled for September 24, 2026, and mailed an open letter urging stockholders to vote 'FOR' all six director nominees on the white universal proxy card. The filing highlights a contested board election against activist investor Patrick Adams through PVG Asset Management Corporation, which holds only 0.35% of shares but nominated a slate lacking FDA regulatory or drug development expertise. Anavex’s Board is refreshing its membership by nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, while appointing Dr. Terrie Kellmeyer as interim CEO following the former CEO's termination in April 2026. The company emphasized its strategy to advance oral blarcamesine across three CNS indications—early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome—and prioritized FDA engagement to establish a regulatory path forward. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.

Anavex Life Sciences Corp. announced plans to refresh its Board of Directors at the 2026 Annual Meeting by nominating two new independent directors, Gautam Patel and Dr. Adrian Senderowicz, while not renominating former CEO Christopher Missling and director Dr. Steffen Thomas. The current board urged stockholders to reject a proxy contest filed by PVG Asset Management Corporation and Patrick S. Adams seeking to replace the entire board with nominees who own only 0.35% of outstanding shares. Interim CEO Dr. Terrie Kellmeyer will oversee operations following Missling's termination for cause, which delayed the filing of the company's quarterly report. The company maintains a strong cash runway and no long-term debt while prioritizing its lead candidate blarcamesine for Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases.